Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma

Fig. 5

JM1-24-3 inhibited melanoma tumor growth and reduced lung metastasis in xenograft athymic nude mice. a Sub-cutaneous tumors were developed with WM266-4 cells on athymic nude mice and treated with JM1-24-3 (n = 11) or with irrelevant mAb (n = 8) (6 mg/kg body wt/i.p.) twice a week and tumor volume was measured every 4 days until day 45. Treatment with JM1-24-3 showed significant reduction in tumor volume (46.9 ± 11.8%; p < 0.01). b Pretreatment with JM1-24-3 (n = 5) or irrelevant mAb (n = 7) (6 mg/kg body wt/i.p/twice per week) was done one day before tail vein injection of WM266-4 cells on athymic nude mice followed by treatment till 45 days. All mice were sacrificed at day 45 and their lungs were harvested and stained with H&E and the number of metastatic tumor colonies was counted. Treatment with JM1-24-3 showed significantly fewer colonies (p < 0.05)

Back to article page